Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,700 GBX | +1.64% | +3.03% | +17.29% |
09:54am | GSK Raises Outlook for 2024 as Higher First-quarter Turnover Boosts Confidence | MT |
09:52am | GSK expects momentum to continue after strong first quarter | AN |
Sales 2024 * | 31.48B 39.3B | Sales 2025 * | 33.38B 41.68B | Capitalization | 68.36B 85.35B |
---|---|---|---|---|---|
Net income 2024 * | 5.66B 7.07B | Net income 2025 * | 6.4B 7.99B | EV / Sales 2024 * | 2.56 x |
Net Debt 2024 * | 12.17B 15.19B | Net Debt 2025 * | 8.93B 11.15B | EV / Sales 2025 * | 2.32 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
10.7
x | Employees | 70,212 |
Yield 2024 * |
3.64% | Yield 2025 * |
3.88% | Free-Float | 92.52% |
Latest transcript on GSK plc
1 day | +1.67% | ||
1 week | +2.85% | ||
Current month | -0.62% | ||
1 month | +2.10% | ||
3 months | +10.42% | ||
6 months | +16.91% | ||
Current year | +17.09% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +2.87% | - | |
2.51% | 5 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 1,701 | +1.67% | 604 943 |
24-04-30 | 1,673 | +0.18% | 7,034,532 |
24-04-29 | 1,670 | +1.03% | 5,911,045 |
24-04-26 | 1,653 | +0.76% | 3,990,452 |
24-04-25 | 1,640 | +0.28% | 5,919,718 |
Delayed Quote London S.E., May 01, 2024 at 03:40 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.09% | 85.62B | |
+34.00% | 704B | |
+26.60% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+14.83% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- GSK Stock